FDA Lifts Clinical Hold on Fitusiran

December 15, 2017

Note: The following is edited from a press release from Alnylam Pharmaceuticals. Read the full press release in its entirety here. Alnylam Pharmaceuticals Inc., a RNAi therapeutics company, and Sanofi Genzyme, the specialty care global business unit of Sanofi, announced Dec. 15, 2017, the U.S. Food and Drug Administration (FDA) has lifted the hold on clinical studies with fitusiran, including […]

Biogen’s Hemophilia Therapy Donation Now Available to Patients in Developing World

October 12, 2015

Note: This is an edited form of a press release from Biogen. To read the original release in its entirety, click here. The first shipments of much-needed hemophilia therapy have started to arrive at treatment centers across the developing world Biogen, Swedish Orphan Biovitrum AB (Sobi) and the World Federation of Hemophilia (WFH) announced on Monday, October 12, 2015. […]

New Data Supports Safety & Efficacy of ELOCTATE

August 11, 2015

Note: This is an edited version of a press release from Biogen. To read the original release, click here. _____________________________________ Newly published clinical data demonstrate that people on extended-interval prophylaxis regimens with ELOCTATE® [Antihemophilic Factor (Recombinant), Fc Fusion Protein] experienced low bleeding rates, Biogen and Swedish Orphan Biovitrum AB (Sobi) announced on Monday, August 10, […]

A World Away; But That’s Not So Far

April 17, 2013

My fellow hemo moms are like my sisters. They are the women I can call, text, or email when I need an outlet for my fears and frustrations.  There seems to be an instant sisterhood amongst hemo moms as soon as you connect a group of them – whether that connection takes place in person […]

Sign up for E-mails, Dateline Newsletter, and other ways to stay connected.